Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) boasts of bullish insider sentiment with 33% ownership and they have been buying lately [Yahoo! Finance]
Nautilus Biotechnology (NASDAQ:NAUT) was upgraded by analysts at
Wall St
Nautilus Biotechnology (NASDAQ:NAUT) was downgraded by analysts at
Wall
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging